Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

MicroVision Announces First Quarter 2024 Results


REDMOND, WA / ACCESSWIRE / May 9, 2024 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2024 results.

 

Key Business Highlights for Q1 2024

 

-          Actively engaged in high-volume, top-tier global OEM RFQs for passenger vehicles.

-          Expanding near-term revenue opportunities through direct sales in industrial markets.

-          Working to accumulate non-dilutive cash by leveraging partnerships and licensing opportunities.

-          Increasing cash runway through proactive, disciplined fiscal management.

 

"Energized by global OEM feedback that MicroVision offers the best technical and commercial solutions, we remain confident in our engagement with automotive OEMs and our prospects in high-volume, top-tier, passenger-vehicle RFQs," said Sumit Sharma, MicroVision's Chief Executive Officer. "As we navigate current headwinds in the automotive industry and lidar sector with a healthy balance of optimism and realism, we are aggressively pursuing near-term revenue opportunities in industrial markets and with partnership opportunities, as well as continuing our ethos of fiscal discipline."

 

"I remain committed to steering MicroVision and firmly establishing it as a leading automotive OEM supplier of lidar hardware and software solutions," continued Sharma.

 

Key Financial Highlights for Q1 2024

 

-          Revenue for the first quarter of 2024 was $1.0 million, compared to $0.8 million for the first quarter of 2023 primarily driven by sales of MOVIA sensors to a global commercial trucking OEM.

-          Net loss for the first quarter of 2024 was $26.3 million, or $0.13 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $19.0 million, or $0.11 per share, which includes $2.9 million of non-cash, share-based compensation expense, for the first quarter of 2023.

-          Adjusted EBITDA for the first quarter of 2024 was a $18.7 million loss, compared to a $15.7 million loss for the first quarter of 2023.

-          Cash used in operations in the first quarter of 2024 was $20.8 million, compared to cash used in operations in the first quarter of 2023 of $13.5 million.

-          The Company ended the first quarter of 2024 with $73.1 million in cash and cash equivalents including investment securities, compared to $73.8 million at December 31, 2023.

 

Conference Call and Webcast: Q1 2024 Results

 

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 1:30 PM PT/4:30 PM ET on Thursday, May 9, 2024 to discuss the financial results and provide a business update. Analysts and investors may pose questions to management during the live webcast on May 9, 2024.

 

The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.

 

About MicroVision

 

With offices in the U.S. and Germany, MicroVision is a pioneering company in MEMS-based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology to provide automotive lidar sensors and solutions for advanced driver-assistance systems (ADAS) and for non-automotive applications including industrial, smart infrastructure and robotics. The Company has been leveraging its experience building augmented reality micro-display engines, interactive display modules, and consumer lidar modules.

 

For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc, and LinkedIn at https://www.linkedin.com/company/microvision/.

 

MicroVision, MAVIN, MOSAIK, and MOVIA are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

 

Non-GAAP information

 

To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measures "adjusted EBITDA" and "adjusted Gross Profit." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; bargain purchase gain; share-based compensation; and restructuring charges. Adjusted Gross Profit is calculated as GAAP gross Profit before share-based compensation expense and the amortization of acquired intangibles included in cost of revenue.

 

MicroVision believes that the presentation of adjusted EBITDA and adjusted Gross Profit provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses these non-GAAP measures when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA and adjusted Gross Profit are useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.

 

Adjusted EBITDA and adjusted Gross Profit are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measures should not be construed as an inference that these costs are unusual or infrequent.

 

The Company compensates for limitations of the adjusted EBITDA measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

 

Similarly for Adjusted Gross Profit, the Company compensates for limitations of the measure by prominently disclosing GAAP gross Profit which is the difference between Revenue and Cost of revenue, which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation by backing out share-based compensation expense and the amortization of acquired intangibles included in cost of revenue.

 

Forward-Looking Statements

 

Certain statements contained in this release, including customer engagement and the likelihood of success, opportunities for revenue and cash, expense reduction, market position, product portfolio, product and manufacturing capabilities, and expected revenue, expenses and cash usage are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements; its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

 

Investor Relations Contact

Jeff Christensen

Darrow Associates Investor Relations

[email protected]

 

Media Contact

[email protected]

 

MicroVision, Inc.

Consolidated Balance Sheet

(In thousands)

(Unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

44,298

 

 

$

45,167

 

Investment securities, available-for-sale

 

 

28,770

 

 

 

28,611

 

Restricted cash, current

 

 

71

 

 

 

3,263

 

Accounts receivable, net of allowances

 

 

1,121

 

 

 

949

 

Inventory

 

 

3,738

 

 

 

3,874

 

Other current assets

 

 

4,302

 

 

 

4,890

 

Total current assets

 

 

82,300

 

 

 

86,754

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

8,549

 

 

 

9,032

 

Operating lease right-of-us asset

 

 

13,212

 

 

 

13,758

 

Restricted cash, net of current portion

 

 

1,968

 

 

 

961

 

Intangible assets, net

 

 

16,662

 

 

 

17,235

 

Other assets

 

 

1,491

 

 

 

1,895

 

Total assets

 

$

124,182

 

 

$

129,635

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities and Shareholders' Equity

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable

 

$

2,161

 

 

$

2,271

 

Accrued liabilities

 

 

9,971

 

 

 

8,640

 

Accrued liability for Ibeo business combination

 

 

2,969

 

 

 

6,300

 

Contract liabilities

 

 

213

 

 

 

300

 

Current portion of operating lease liability

 

 

2,167

 

 

 

2,323

 

Other current liabilities

 

 

270

 

 

 

669

 

Total current liabilities

 

 

17,751

 

 

 

20,503

 

 

 

 

 

 

 

 

 

 

Operating lease liability, net of current portion

 

 

12,358

 

 

 

12,714

 

Other long-term liabilities

 

 

270

 

 

 

614

 

Total liabilities

 

 

30,379

 

 

 

33,831

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' Equity

 

 

 

 

 

 

 

 

Common stock at par value

 

 

206

 

 

 

195

 

Additional paid-in capital

 

 

885,119

 

 

 

860,765

 

Accumulated other comprehensive loss

 

 

157

 

 

 

210

 

Accumulated deficit

 

 

(791,679

)

 

 

(765,366

)

Total shareholders' equity

 

 

93,803

 

 

 

95,804

 

Total liabilities and shareholders' equity

 

$

124,182

 

 

$

129,635

 

 

MicroVision, Inc.

Consolidated Statement of Operations

(In thousands, except earnings per share data)

(Unaudited)

 

 

 

Three months ended March 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

956

 

 

$

782

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

1,277

 

 

 

544

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

(321

)

 

 

238

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expense

 

 

17,311

 

 

 

12,692

 

Sales, marketing, general and administrative expense

 

 

9,078

 

 

 

8,737

 

Total operating expenses

 

 

26,389

 

 

 

21,429

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(26,710

)

 

 

(21,191

)

 

 

 

 

 

 

 

 

 

Bargain purchase gain

 

 

-

 

 

 

1,706

 

Other income, net

 

 

631

 

 

 

639

 

 

 

 

 

 

 

 

 

 

Net loss before taxes

 

$

(26,079

)

 

$

(18,846

)

 

 

 

 

 

 

 

 

 

Income tax expense

 

 

(234

)

 

 

(181

)

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(26,313

)

 

$

(19,027

)

 

 

 

 

 

 

 

 

 

Net income (loss) per share - basic and diluted

 

$

(0.13

)

 

$

(0.11

)

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding - basic and diluted

 

 

196,748

 

 

 

174,703

 

 

MicroVision, Inc.

Consolidated Statement of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Three months ended March 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(26,313

)

 

$

(19,027

)

Adjustments to reconcile net loss to

 

 

 

 

 

 

 

 

net cash used in operations

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,800

 

 

 

2,524

 

Impairment of property and equipment

 

 

13

 

 

 

-

 

Bargain purchase gain

 

 

-

 

 

 

(1,706

)

Share-based compensation expense

 

 

3,743

 

 

 

2,949

 

Inventory write-down

 

 

9

 

 

 

29

 

Net accretion of premium on short-term investments

 

 

(288

)

 

 

(396

)

Change in:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(172

)

 

 

(506

)

Contract assets

 

 

-

 

 

 

(192

)

Inventory

 

 

102

 

 

 

(87

)

Other current and non-current assets

 

 

992

 

 

 

647

 

Accounts payable

 

 

(527

)

 

 

1,629

 

Accrued liabilities

 

 

1,331

 

 

 

2,017

 

Contract liabilities and other current liabilities

 

 

(480

)

 

 

(711

)

Operating lease liabilities

 

 

(639

)

 

 

(669

)

Other long-term liabilities

 

 

(330

)

 

 

17

 

Net cash used in operating activities

 

 

(20,759

)

 

 

(13,482

)

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

Sales of investment securities

 

 

7,900

 

 

 

22,000

 

Purchases of investment securities

 

 

(7,805

)

 

 

(3,898

)

Purchases of property and equipment

 

 

(114

)

 

 

(615

)

Cash paid for Ibeo business combination

 

 

(3,263

)

 

 

(11,233

)

Net cash provided by (used in) investing activities

 

 

(3,282

)

 

 

6,254

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Principal payments under finance leases

 

 

-

 

 

 

(6

)

Proceeds from stock option exercises

 

 

62

 

 

 

-

 

Net proceeds from issuance of common stock

 

 

20,956

 

 

 

12,691

 

Net cash provided by financing activities

 

 

21,018

 

 

 

12,685

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

 

(31

)

 

 

-

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

 

(3,054

)

 

 

5,457

 

Cash, cash equivalents and restricted cash at beginning of period

 

 

49,391

 

 

 

21,954

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash, cash equivalents and restricted cash at end of period

 

$

46,337

 

 

$

27,411

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of

 

March 31, 2024 and December 31, 2023:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

 

December 31,

 

 

 

 

2024

 

 

 

2023

 

Cash and cash equivalents

 

$

44,298

 

 

$

45,167

 

Restricted cash

 

 

2,039

 

 

 

4,224

 

Cash, cash equivalents and restricted cash

 

 

46,337

 

 

 

49,391

 

 

MicroVision, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(In thousands, except earnings per share data)

(Unaudited)

 

 

 

Three months ended March 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Gross Profit:

 

 

 

 

 

 

Gross Profit

 

$

(321

)

 

$

238

 

Share-based compensation expense

 

 

-

 

 

 

-

 

Amortization of acquired intangibles

 

 

387

 

 

 

255

 

Adjusted Gross Profit

 

$

66

 

 

$

493

 

 

 

 

 

 

 

 

 

 

Reconciliation of Non-GAAP Loss:

 

 

 

 

 

 

 

 

GAAP Net loss

 

$

(26,313

)

 

$

(19,027

)

Other Income/Expense,net

 

 

(631

)

 

 

(639

)

Income taxes

 

 

234

 

 

 

181

 

Depreciation amortization

 

 

1,800

 

 

 

2,524

 

Bargain purchase gain

 

 

-

 

 

 

(1,706

)

Share-based compensation expense

 

 

3,743

 

 

 

2,949

 

Restructuring costs

 

 

2,474

 

 

 

-

 

Adjusted EBITDA

 

$

(18,693

)

 

$

(15,718

)

 

 

 

 

 

 

 

 

 

 

SOURCE: MicroVision, Inc.

MicroVision Inc Stock

€1.00
-1.690%
A loss of -1.690% shows a downward development for MicroVision Inc.
The community is currently still undecided about MicroVision Inc with 2 Buy predictions and 0 Sell predictions.
With a target price of 4 € there is potential for a 300.64% increase which would mean more than doubling the current price of 1.0 € for MicroVision Inc.
Like: 0
Share

Comments